Updated interim results of the safety and efficacy of different lenalidomide starting dose regimens in patients with relapsed or refractory (REL/REF) chronic lymphocytic leukemia (CLL) (CC-5013-CLL-009 study)

This article has no abstract
Epistemonikos ID: 3ca7aa11bec36fda39d5d795571f665f99be7bdf
First added on: Feb 05, 2025